Preclinical Data on Ariad Pharmaceuticals, Inc.'s Novel Investigational mTOR Inhibitor, Deforolimus, to Be Presented at the American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new preclinical data on deforolimus, ARIAD’s mTOR inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, being held April 12 to 16, 2008.